InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,167.60
(
0.00%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.18
(
0.06%
)
Bitcoin
66,216.02
(
-0.63%
)
Post# of 647234
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

BioSpecialist

Send PM Follow Ignore
Followers 129
Posts 2150
Boards Moderated 1
Alias Born 12/27/2007

BioSpecialist

Re: None

Monday, 01/27/2020 9:31:33 AM

Monday, January 27, 2020 9:31:33 AM

Post# of 647234
BXRX =MC $79 M--FDA Decision NEXT month for Non-Opioid Pain Drug-Cash $20 M - O/S 9 M / --UNKNOWN Gem = 500%+ Upside
https://www.sec.gov/Archives/edgar/data/1780097/000119312519306813/g841356ex99_1s7g1.jpg
Baudax Bio,(BXRX) a specialty pharmaceutical company focused on therapeutics for acute care settings, today announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA goal date of February 20, 2020 for its decision on the New Drug Application (NDA) for intravenous (IV) meloxicam for the management of moderate to severe pain.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up